Arginine with whole brain radiation for cancer that has spread to the brain
Original title: Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test of the drug in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing how to safely give arginine along with whole-brain radiation: Radiation given to the whole brain, rather than aimed at one spot. It is used when there are too many tumors to aim at one at a time. See the glossary.
Who this trial is for. This trial is for people whose cancer has spread to the brain. It tests arginine given by mouth or through a vein, with whole-brain radiation: Radiation given to the whole brain, rather than aimed at one spot. It is used when there are too many tumors to aim at one at a time. See the glossary.
Where it stands. This trial has not reported results. It is measuring the level of arginine in the blood before and after a dose. It is also checking how safe arginine is when given with radiation. The best dose is not known yet.
What this means, and what it doesn't
What it could mean: Arginine is an amino acid, one of the building blocks of protein in the body. This study is trying to learn the best way and the best amount to give it. Someone who fits the study might ask their care team about it.
What it doesn't mean: This does not mean arginine helps people with brain metastases. A trial is a test, not a proven treatment. Being in one is not a promise that you will feel better or live longer. It is not a cure.
Source: ClinicalTrials.gov, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.